Financing Adaptogenic Mushroom Companies: Seven Basic Regulatory Points to Understand
By Charles Alovisetti, Joshua Kappel, Andrea Golan
Dec 2, 2021
Aside from a small number of companies the FDA has permitted to pursue the development of psilocybin therapies (e.g., Compass), the majority of psychedelic mushroom sales in the U.S. currently violate both state and federal law. As we wait for federal legalization and/or state-regulated psilocybin markets to emerge, what can a motivated entrepreneur interested in mycelium pursue?
One option is adaptogenic or functional mushrooms—non-psychoactive mycelium promoted for energy and general health. The functional mushroom industry focuses on selling non-psychoactive mushrooms as dietary supplements, food, or as an ingredient in conventional foods. Common mushrooms sold for these purposes include chaga, reishi, shiitake, lion's mane, cordyceps, and turkey tail. It's a sizable industry—one firm pegged the size of the global market for functional mushrooms at $25 billion in 2020.
While adaptogenic mushrooms can be sold in compliance with state and federal law, there are still legal guardrails. When raising capital in a novel and heavily regulated industry, it is good practice to understand the relevant regulatory restraints so that you can explain to investors how you intend to comply. To that end, here are the regulatory basics you need to understand in seven points (it goes without saying this article grossly simplifies a complex area of law):
1. Controlled Substances Act (CSA)
The Controlled Substances Act (1970) is the statute that establishes federal U.S. drug policy and regulates certain substances that are set forth on five schedules. Schedule I includes substances that have a high potential for abuse, have no currently accepted medical use in the U.S., and for which there is no accepted safe use under medical supervision. The CSA has been repeatedly amended since being signed into law in 1970, most notably by the 1986 Federal Analogue Act. This act captures substances not expressly scheduled under the CSA by also making unlawful substances that share a chemical structure "substantially similar" to that of a Schedule I and II controlled substance and have an actual or intended effect on the central nervous system "substantially similar" to or greater than a Schedule I or Schedule II controlled substance (known as a "controlled substance analogue").
Psilocybin, psilocin, and marijuana are all listed on schedule I. But unless a mushroom product contains psilocybin or psilocin, or an analogue of those substances, it will not be subject to the strict limitations on sale outlined in the CSA.
2. Federal Food Drug & Cosmetic Act (FD&C Act)
The principal statute in the U.S. governing the safety of most foods, food additives, and dietary supplements, including non-psychoactive mushrooms added to or sold as foods or dietary supplements, is the FD&C Act. It dates to the Roosevelt Administration and has been significantly updated since its implementation. Significant amendments include the Food Additives Amendment of 1958, the Dietary Supplement Health and Education Act of 1994 (DSHEA), and the Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006.
3. Advertising & Labeling Requirements
There are strict restrictions concerning the advertisement and labeling of food and dietary supplements, including adaptogenic mushrooms. In fact, violations of these restrictions are one of the more common triggers for enforcement actions. As an example, the FDA sent a letter to a mushroom supplement seller pointing out that claims made by the marketer that the mushroom supplement is intended to prevent, treat, diagnose, or cure disease renders the supplement an unapproved drug. The FDA has the primary responsibility for dealing with labeling and the FTC for the advertising of dietary supplements—you will often see joint letters sent by both agencies because of this dual mandate (see this letter as an example).
4. Current Good Manufacturing Practices (cGMP)
Anyone who manufactures, packages, labels, or holds dietary supplements must follow the current good manufacturing practices published by the FDA on June 25, 2007. These guidelines are meant to help ensure product safety. But the FDA does not actively enforce cGMP compliance prior to sale. Instead, the FDA relies on facility inspections and reports of violations. There are third parties that offer cGMP certification labels.
Note that under the guidance provided by the FDA, distributors who work with contract manufacturers are obligated to know how manufacturing is performed so that packaging and labeling can be performed correctly and the decision to release the product for distribution is appropriately made.
5. Reporting Adverse Events
The Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006 created certain reporting and recordkeeping requirements for adverse events related to supplements. Essentially, if someone dies or requires medical intervention after consuming a mushroom supplement, a specific form needs to be sent to the FDA.
6. Pre-approval Likely Not Required
Generally, federal law does not require dietary supplements to be proven safe to the FDA's satisfaction before they are marketed unless they contain a "new dietary ingredient" (note that food and food additives are regulated differently). FDA premarket approval is typically not required for dietary supplements. However, new dietary ingredients (NDI), defined as ingredients that were not marketed in the U.S. prior to October 15, 1994, do require a notification to the FDA at least 75 days before introduction into interstate commerce (commonly referred to as an NDI notification).
Another notable restriction, which has become a significant issue with CBD, is the so-called Drug Preclusion Rule. This rule prohibits the sale of a substance approved as a new drug, or licensed biologic or authorized for investigation as a new drug or biologic, except in the case where the substance was marketed as a dietary supplement or as a food prior to such approval or authorized investigation.
7. Selling Adaptogenic Mushrooms as Foods or Food Additives
The FD&C Act creates a distinction between "food" and "food additives," which has meaningful consequences for producers of adaptogenic mushrooms because it affects the ease with which FDA may regulate the substance's sale. A substance regulated as a "food" is presumed safe and FDA can prevent its sale only if FDA proves by a preponderance of evidence that it is injurious to health. By contrast, a "food additive" carries the opposite presumption. A "food additive" is presumed unsafe unless and until the manufacturer shows the additive is generally recognized as safe (GRAS) for its intended use. In other words, if a substance is manufactured with the intent of being added to conventional foods, it must be either GRAS, or approved by FDA as a "food additive," both of which require "reasonable certainty" of safety.
There is an exemption to this requirement that sellers of adaptogenic mushrooms often rely on, referred to as the "common use" exemption. Under the common use exemption, a food ingredient is automatically GRAS if it was commonly used in food prior to 1958, when the Food Additives Amendment was added to the FD&C Act, and that "common use" demonstrates the ingredient to be safe.
Alternatively, if an additive is unable to meet the "common use" exemption because it is new or used in new ways, GRAS status is achieved by adequately showing through scientific procedures that it is safe under the conditions of intended use (meaning safe at a particular level in a particular type of food). Once a food producer establishes GRAS status, it may send additive-containing products to market free of any premarket approval requirement.
If you’re interested in starting or financing a business in the adaptogenic mushrooms industry, the regulatory restraints listed above will help you to better articulate your compliance plan to potential investors. But remember, this is a complex area of law and this article only touches on the basics. Reach out to VS’s regulatory team if you have questions.